CR20250091A - Derivados de ftalazina útiles como inhibidores de la proteína receptora 3 similar a nod. - Google Patents

Derivados de ftalazina útiles como inhibidores de la proteína receptora 3 similar a nod.

Info

Publication number
CR20250091A
CR20250091A CR20250091A CR20250091A CR20250091A CR 20250091 A CR20250091 A CR 20250091A CR 20250091 A CR20250091 A CR 20250091A CR 20250091 A CR20250091 A CR 20250091A CR 20250091 A CR20250091 A CR 20250091A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
nlrp3
nod
disease
receptor protein
Prior art date
Application number
CR20250091A
Other languages
English (en)
Inventor
Prabha Karnachi
Donna A A W Hayes
Rohan Rajiv Merchant
Madeleine Eileen Kieffer
Kyle S Mcclymont
Zheng Tan
Emma H Southgate
Essam Metwally
Brandon M Taoka
Anilkumar G Nair
Jillian Rose Sanzone
Ning Qi
Nunzio Sciammetta
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of CR20250091A publication Critical patent/CR20250091A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los nuevos compuestos de la fórmula estructural (I), y las sales farmacéuticamente aceptables de los mismos, son inhibidores de NLRP3 y pueden ser útiles en el tratamiento, prevención, abordaje, mejora, control y supresión de enfermedades mediadas por NLPR3. Los compuestos de la presente invención pueden ser útiles en el tratamiento, la prevención o el abordaje de enfermedades, trastornos y afecciones mediados por NLRP3 tales como, pero sin limitación, gota, pseudogota, CAPS, fibrosis por EHNA, insuficiencia cardíaca, pericarditis idiopática, dermatitis atópica, enfermedad inflamatoria intestinal, enfermedad de Alzheimer, enfermedad de Parkinson y traumatismo craneoencefálico.
CR20250091A 2022-09-23 2023-09-21 Derivados de ftalazina útiles como inhibidores de la proteína receptora 3 similar a nod. CR20250091A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263409432P 2022-09-23 2022-09-23
PCT/US2023/033320 WO2024064245A1 (en) 2022-09-23 2023-09-21 Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3

Publications (1)

Publication Number Publication Date
CR20250091A true CR20250091A (es) 2025-04-10

Family

ID=88315924

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250091A CR20250091A (es) 2022-09-23 2023-09-21 Derivados de ftalazina útiles como inhibidores de la proteína receptora 3 similar a nod.

Country Status (19)

Country Link
US (1) US20240124451A1 (es)
EP (1) EP4590672A1 (es)
JP (1) JP7707451B2 (es)
KR (1) KR20250069659A (es)
CN (1) CN119907797A (es)
AR (1) AR130548A1 (es)
AU (1) AU2023347443A1 (es)
CA (1) CA3268263A1 (es)
CL (1) CL2025000835A1 (es)
CO (1) CO2025003580A2 (es)
CR (1) CR20250091A (es)
DO (1) DOP2025000068A (es)
GE (1) GEAP202516743A (es)
IL (1) IL319619A (es)
JO (1) JOP20250062A1 (es)
MX (1) MX2025003369A (es)
PE (1) PE20251293A1 (es)
TW (1) TW202421626A (es)
WO (1) WO2024064245A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2025026252A1 (en) * 2023-08-02 2025-02-06 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2026057634A1 (en) * 2024-09-11 2026-03-19 Sanofi Crystalline form of a pyridazine nlrp3 inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533356A (en) * 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
WO2006004589A2 (en) * 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
US8153633B2 (en) * 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
US8222251B2 (en) * 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
UA102250C2 (ru) * 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
MX2011004683A (es) * 2008-11-03 2011-06-20 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida.
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
US10947241B2 (en) * 2016-10-28 2021-03-16 Seoul National University Hospital Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same
EP3697758B1 (en) 2017-10-17 2022-07-06 Novartis AG Sulphonamides and compositions thereof for treating conditions associated with nlrp activity
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
US20220267276A1 (en) 2018-07-03 2022-08-25 Novartis Ag Nlrp modulators
EP3823974A1 (en) 2018-07-20 2021-05-26 F. Hoffmann-La Roche AG Sulfonimidamide compounds as inhibitors of interleukin-1 activity
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
WO2020037116A1 (en) 2018-08-17 2020-02-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN115279739B (zh) 2020-03-27 2025-07-22 尼科治疗有限公司 取代哒嗪化合物
WO2021209539A1 (en) 2020-04-15 2021-10-21 Janssen Pharmaceutica Nv Pyrrolo[1,2-d][1,2,4]triazine-2-yl-acetamides as inhibitors of the nlrp3 inflammasome pathway
AU2021257619A1 (en) 2020-04-15 2022-12-15 Janssen Pharmaceutica Nv Pyrazolo[1,5-d][1,2,4]triazine-5(4H)-acetamides as inhibitors of the NLRP3 inflammasome pathway
AU2021279305A1 (en) 2020-05-28 2023-02-09 Janssen Pharmaceutica Nv Compounds
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CR20240093A (es) * 2021-08-25 2024-05-23 Ptc Therapeutics Inc Inhibidores de NLRP3
JP2025023868A (ja) * 2022-09-23 2025-02-17 メルク・シャープ・アンド・ドーム・エルエルシー Ｎｏｄ様受容体タンパク質３の阻害剤として有用なフタラジン誘導体

Also Published As

Publication number Publication date
IL319619A (en) 2025-05-01
MX2025003369A (es) 2025-05-02
JP7707451B2 (ja) 2025-07-14
AU2023347443A1 (en) 2025-04-03
WO2024064245A1 (en) 2024-03-28
JOP20250062A1 (ar) 2025-03-19
CO2025003580A2 (es) 2025-04-16
AR130548A1 (es) 2024-12-18
GEAP202516743A (en) 2025-08-11
CA3268263A1 (en) 2024-03-28
PE20251293A1 (es) 2025-05-14
US20240124451A1 (en) 2024-04-18
EP4590672A1 (en) 2025-07-30
TW202421626A (zh) 2024-06-01
DOP2025000068A (es) 2025-04-30
CL2025000835A1 (es) 2025-07-25
JP2025512651A (ja) 2025-04-22
CN119907797A (zh) 2025-04-29
KR20250069659A (ko) 2025-05-19

Similar Documents

Publication Publication Date Title
CL2025000835A1 (es) Derivados de ftalazina útiles como inhibidores de la proteína receptora 3 similar a nod.
KR102488479B1 (ko) 인플루엔자 바이러스 감염에 사용하기 위한 인돌
US20240425437A1 (en) Derivatives of sobetirome
CO2022007946A2 (es) Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de cftr deficiente
EP2597953A4 (en) METHOD FOR THE TREATMENT OF EYE DISEASES USING KINASE-INHIBITOR COMPOUNDS IN PRODRUG FORMS
CR20250413A (es) Compuestos de pirido[4,3–d]pirimidina
WO2013052263A2 (en) Antifungal compounds
WO2013040528A1 (en) Antimicrobial compounds
ES2881850T3 (es) Compuestos de carmato de fenil alquilo para su uso en la prevención o tratamiento de la epilepsia o síndrome relacionado con la epilepsia
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
CO2025017164A2 (es) Heterociclos bicíclicos 5,6 insaturados útiles como inhibidores de la proteína receptora 3 similar a nod
WO2013040527A1 (en) Antimicrobial compounds
EA202190621A1 (ru) Фармацевтическая композиция, содержащая антитромбоцитарное средство и ингибитор секреции желудочной кислоты
EA006597B1 (ru) Ингибиторы аминотрансфераз, зависимых от аминокислот с разветвленной цепью, и их применение в лечении диабетической ретинопатии
KR20110117088A (ko) 통증 및 기타 질병을 치료하기 위한 화합물 및 방법
US20080261984A1 (en) Use of S,S-Reboxetine in the Treatment of Pain
WO2024249389A3 (en) 5,6 saturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
WO2015081822A1 (zh) 3-呋喃基-2-氰基-2-丙烯酰胺衍生物及其制备方法、药物组合物和用途
AR134647A1 (es) Derivados de azaindazol útiles como inhibidores de la proteína 3 del receptor similar a nod
MY205498A (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
AR134646A1 (es) Derivados de indazol útiles como inhibidores de la proteína 3 del receptor similar a nod
WO2013040526A1 (en) Antimicrobial compounds
US20130281506A1 (en) Combination of a non-steroidal anti-inflammatory drug with an anti-histaminic drug intended for ophthalmic use
US10556870B2 (en) Imidazole compounds as EAAT3 inhibitors
WO2024026102A2 (en) Prodrugs for delivery of testosterone to the central nervous system